Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 13/20 | 0.35 |
| ▸ | ULK1 | O75385 | 1/20 | 0.33 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 2/20 | 0.32 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30850669 | 0.78 | CDK4 (0.35) | CDK1ULK1ULK2CDK4MAPK3 | |
| SCHEMBL1451044 | 0.76 | — | — | |
| SCHEMBL5072697 | 0.76 | EGFR (0.36) | CDK1ULK1KDM4EALDH1A1GLA | |
| SCHEMBL7522894 | 0.76 | KDM4E (0.33) | CDK1KDM4EALDH1A1GLAGAA | |
| SCHEMBL9356677 | 0.76 | KDM4E (0.33) | CDK1KDM4EALDH1A1GLAGAA | |
| SCHEMBL5828206 | 0.76 | KDM4E (0.36) | CDK1KDM4EALDH1A1GLAGAA | |
| SCHEMBL30677393 | 0.76 | KDM4E (0.36) | CDK1KDM4EALDH1A1GLAGAA | |
| SCHEMBL30850504 | 0.76 | EGFR (0.36) | CDK1ULK1KDM4EALDH1A1GLA | |
| SCHEMBL4480587 | 0.76 | KDM4E (0.33) | CDK1KDM4EALDH1A1GLAGAA | |
| SCHEMBL30199097 | 0.74 | CDK1 (0.34) | CDK1ULK1ULK2CDK4MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179290-A1 | Production method of fluorinated purine nucleoside derivative, intermediate therefor and production method thereof | AJINOMOTO CO. INC. (JP) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179290-A1 | Production method of fluorinated purine nucleoside derivative, intermediate therefor and production method thereof | PNP, NUDT1, ADAR | CDK1 2570/4885ULK1 3937/4885ULK2 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.